On October 31, the U.S. District Court for the Eastern District of Virginia granted a preliminary injunction blocking the U.S. Patent Office’s Claims and Continuations Rules from taking effect. While the rules are on hold, nutraceutical companies need to remain informed so they can make decisions that will maximize the value of their patent portfolios during these uncertain times. In her byline on www.nutraingredients-usa.com, Foley’s Courtenay Brinckerhoff highlights some of the arguments by Smithkline Beecham Corporation (GSK), who challenged the court on the rules, as well as the court’s decisions and the possible impact on nutraceutical companies
Click here for the full article.
Author(s)
Related Insights
18 February 2025
Labor & Employment Law Perspectives
Noncompete Bans – Next Up: Ohio
This month, Ohio joined the list of states with pending legislation to ban noncompetes. With the FTC noncompete ban blocked on a nationwide basis last year, Ohio lawmakers introduced a bill on February 5, 2025, that would ban noncompete contracts as a condition of employment in the state.
18 February 2025
DEA Delays Final Buprenorphine Rule
The Department of Health and Human Services and the Drug Enforcement Administration have delayed the effective date of the final rule regarding telemedicine prescribing of buprenorphine to March 21, 2025, and have requested public comments on the rule.
17 February 2025
Foley Viewpoints
6 Steps to Manage Tariff Risks in a Trade War
As Trump seeks to raise U.S. tariffs (which currently tend to be among the lowest worldwide), manufacturers, distributors, retailers, and other companies that frequently import must determine the best strategy to deal with the resulting uncertainties.